ANALYSIS OF THE AXONAL DEGENERATION FOLLOWING INFLAMMATORY DEMYELINATION IN MULT

多发性骨髓瘤炎性脱髓鞘后轴突变性的分析

• 批准号: 7604738
• 负责人: PETER A CALABRESI
• 金额: $ 0.02万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604738
• 关键词: 3-Dimensional; Accounting; Acute; Anisotropy; Area; Atrophic; Axon; Clinical; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Computer software; Demyelinations; Diffusion Magnetic Resonance Imaging; Disease; Disruption; Distal; Distant; Enhancing Lesion; Fiber; Funding; Gadolinium; Goals; Grant; Image; Individual; Inflammation; Inflammatory; Institution; Lesion; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Measurement; Measures; Mediating; Myelin; Outcome Measure; Pathology; Pathway interactions; Patients; Pharmaceutical Preparations; Phase II Clinical Trials; Phase II/III Trial; Protons; Research; Research Personnel; Resources; Site; Source; Specificity; Staging; Surrogate Markers; Thinking; Time; Translating; United States National Institutes of Health; Wallerian Degeneration; base; bench to bedside; brain tissue; density; disability; functional disability; improved; interest; reconstruction; repaired; white matter

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A major goal in translating neuroprotective and neuroreparative strategies for MS from the bench to the bedside is to develop surrogate measures of myelin and axon integrity that can be used in phase II clinical trials to screen for preliminary efficacy. The utility of gadolinium-enhancing lesions as a surrogate marker of inflammation in phase II/III trials of immunomodulatory drugs is now well accepted. Nonetheless, even in the absence of apparent inflammation, clinical disability progresses. This is thought to occur as a result of axon degeneration mediated by numerous downstream factors. Radiological studies have demonstrated evidence of distant Wallerian degeneration and atrophy that ensue months to years after active inflammatory demyelination (230). The correlation between disability and conventional measures such as T1 volume (post-gadolinium), T2 volume, and atrophy or T1 black holes is only modest (correlation coefficients between 0.3 and 0.6 in a variety of studies), presumably because all of these measures lack specificity for permanent brain tissue pathology. Recent advances in magnetic resonance imaging (MRI) such as magnetization transfer imaging (MTI), proton magnetic resonance spectroscopy (1H-MRS), and diffusion tensor imaging (DTI) offer promise as more sensitive and specific measures of underlying structural pathology. There is a great need to develop and optimize these measures so as to be able to non-invasively quantify the extent of demyelination and axon degeneration in MS patients. We are focusing on developing DTI and MTI to allow quantitative measurement of pathology along white-matter tracts, which can then be used as outcome measures for clinical trials of potential neuroprotective and neuroreparative agents. DTI gives information on the directionality and integrity of white-matter tracts. MTI has been shown to be associated with both axon density and myelin integrity, and therefore may be relevant to tracking local and distant changes in axons that pass through areas of damaged myelin, as well as a measure of myelin repair. Fiber-tracking software allows the 3 dimensional reconstruction of specific pathways distal and proximal to a region of interest (ROI) or between two or more ROIs. In this way, multiple types of quantitative information can then be acquired both locally and at distant sites from an acute inflammatory lesion. Moreover, we can interrogate the reconstructed pathways to measure changes over time in an individual patient. Since all of the MR images are coregistered we can compare DTI and MTI tract specific information, which may improve our ability to discern different pathologies along the trajectories. The aims of this project are based on the notions that: (1) there is significant axon damage both within and distant from the acute inflammatory demyelinating MS plaque; and (2) progressive changes in axon integrity occur in the chronically demyelinated setting and account for the disabling progressive stages of the disease. We hypothesize that: (1) fractional anisotropy (FA) predominantly reflects disruption of the integrity of axons whereas the magnetization transfer ratio (MTR) predominantly reflects changes in myelin integrity; and (2) the extent and duration of white-matter tract damage in MS patients, as measured by FA and MTR will have concurrent and predictive validity for functional impairment related to the involved pathways.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 将MS的神经保护和神经修复策略从实验室转化到床边的主要目标是开发可用于II期临床试验以筛选初步疗效的髓鞘和轴突完整性的替代措施。在免疫调节药物的II/III期试验中，钆增强病变作为炎症的替代标志物的实用性现在被广泛接受。尽管如此，即使没有明显的炎症，临床残疾的进展。这被认为是由许多下游因子介导的轴突变性的结果。 放射学研究显示，活动性炎性脱髓鞘后数月至数年可发生远端沃勒变性和萎缩（230）。残疾与常规测量（如T1体积（钆后），T2体积和萎缩或T1黑洞）之间的相关性仅为适度（各种研究中的相关系数在0.3和0.6之间），可能是因为所有这些测量都缺乏对永久性脑组织病理学的特异性。 磁共振成像（MRI）的最新进展，如磁化传递成像（MTI），质子磁共振波谱（1H-MRS）和扩散张量成像（DTI）提供了更敏感和更具体的措施，潜在的结构病理的承诺。非常需要开发和优化这些措施，以便能够非侵入性地量化MS患者的脱髓鞘和轴突变性的程度。 我们正致力于开发DTI和MTI，以允许沿沿着白质束的病理学的定量测量，然后可以将其用作潜在的神经保护和神经修复剂的临床试验的结果测量。弥散张量成像提供了白质束的方向性和完整性的信息。MTI已被证明与轴突密度和髓磷脂完整性相关，因此可能与跟踪穿过受损髓磷脂区域的轴突的局部和远端变化以及髓磷脂修复的测量有关。纤维跟踪软件允许对感兴趣区域（ROI）远端和近端或两个或多个ROI之间的特定通路进行三维重建。以这种方式，然后可以在局部和在远离急性炎症病变的部位处获得多种类型的定量信息。此外，我们可以询问重建的通路，以测量个体患者随时间的变化。由于所有的MR图像都是共配准的，我们可以比较DTI和MTI束的特定信息，这可以提高我们辨别沿着轨迹的不同病理的能力。 该项目的目的基于以下概念：（1）在急性炎症性脱髓鞘MS斑块内和远离急性炎症性脱髓鞘MS斑块处均存在显著的轴突损伤;以及（2）轴突完整性的进行性变化发生在慢性脱髓鞘环境中，并导致疾病的致残性进行性阶段。我们假设：（1）各向异性分数（FA）主要反映轴突完整性的破坏，而磁化传递率（MTR）主要反映髓鞘完整性的变化;（2）MS患者白质束损伤的程度和持续时间，如FA和MTR所测量的，将对与相关通路相关的功能损害具有并发和预测有效性。